BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200218
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T060745
CREATED:20191017T094701Z
LAST-MODIFIED:20191017T094701Z
UID:22911-1581984000-1582243199@www.pharmajournalist.com
SUMMARY:Disposable Solutions for Bio Manufacturing
DESCRIPTION:Now in it’s 12th year\, the 2020 Disposable Solutions for Biomanufacturing Forum is the only global forum that focuses on the use of disposable products and single use systems in biomanufacturing. Our attendees will be guided through their journey and understand how they can run 100% disposable sites and scale their manufacturing capabilities with our newly designed program focused on implementation\, systems management and future technology. \n \nThe three packed days will consist of case studies and interactive sessions to identify new technologies\, determine how to approach automated systems\, transition to continuous processes and learn how to implement best practice in system testing & life cycle management! \nTo learn more about Disposable Solutions for Bio Manufacturing and to register online\, visit http://bit.ly/2Mp6lEs
URL:https://www.pharmajournalist.com/event/disposable-solutions-for-bio-manufacturing/
LOCATION:Leonardo Royal Hotel Berlin Alexanderplatz\, Berlin\, Germany\, Germany
ORGANIZER;CN="IQPC":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T060745
CREATED:20171019T063951Z
LAST-MODIFIED:20191004T082421Z
UID:3496-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:RNA Therapeutics
DESCRIPTION:SMi Group are pleased to present the 11th Annual RNA Therapeutics Conference and Focus Day in London on February 18th – 20th 2020. \nThe field of RNA therapeutics is rapidly expanding\, and the potential for using RNA drugs for personalised medicines and immunotherapy\, as well as to address genetic\, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come. \n \nThe event will focus on the latest research and developments on delivery system technologies that aim to tackle more difficult targets within the human body. This overarching topic warrants high focus and therefore\, for the first time in the series\, introduce a focus day on Oligonucletide Delivery Systems. The main conference will focus on current developments in the area of mRNA therapeutics in immunotherapy and vaccination. \nNEW FOR 2020: RNA Therapeutics Focus Day – Oligonucleotide Delivery Systems \nIntroducing the only RNA therapeutics conference to hold a full day exploring alternatives to oligonucleotide delivery systems. The global antisense and RNA therapeutics market is expected to expand at a compound annual growth rate (CAGR) of 8.6% between 2019 and 2025\, projected to reach $1.81 billion\, this focus day will assess the growing need for research and development of novel delivery approaches to expand the current delivery methods in today’s market. \nHow will you benefit? \n\nDiscuss the innovations in oligonucleotide delivery systems\nExplore the latest developments in RNA delivery agents and RNA-based therapeutics\nLearn from case studies on clinical developments with leading RNA therapeutics companies and regulatory bodies\nRevisit the challenges for clinical translation of RNA-based therapeutics\nEvaluate the applications of RNA-based drugs for modulation of gene and protein expression\, and genome editing\nGain an expert view on new and upcoming regulatory updates and industry implications\n\nNetwork and learn from leading professionals such as: \nCHAIR FOR 2020 \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFEATURED SPEAKERS INCLUDE: \n\nShalini Andersson\, Chief Scientist New Therapeutic Modalities\, AstraZeneca\nChristian Plank\, CTO\, Ethris\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\nKirsty Wydenbach\, Deputy Unit Manager\, Clinical Trials Unit\, MhRA\nSteven Powell\, CEO\, eTheRNA\nSimon Newman\, CSO\, Nanogenics\nChristiane Niederlaender\, Director\, AMBR Consulting and Formerly\,\nQuality Assessor\, Biologicals\, MhRA\nKlaus Giese\, CEO\, Pantherna Therapeutics\nDavid Blakey\, CSO\, MiNA Therapeutics\nJeffrey Ulmer\, Head Preclinical R&D\, GSK\n\nFor more information and to register\, visit: www.therapeutics-rna.com/pjwb  \nEarly-Bird Rates \nREGISTER BY 31ST OCTOBER TO SAVE £400 \nREGISTER BY 29Th NOVEMBER TO SAVE £200 \nREGISTER BY 13Th DECEMBER TO SAVE £100 \nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #SMiRNA
URL:https://www.pharmajournalist.com/event/rna-therapeutics/
LOCATION:London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200219
DTEND;VALUE=DATE:20200221
DTSTAMP:20260515T060745
CREATED:20191015T105531Z
LAST-MODIFIED:20191015T105531Z
UID:22854-1582070400-1582243199@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual 3D Cell Culture
DESCRIPTION:CHAIRED BY:\nPhilip Hewitt\, UK and Eurotox Registered Toxicologist\, Global Head of Early Investigative Toxicology\, Merck Healthcare KGaA\nStefan Przyborski\, Professor of Cell Technology\, Durham university \nDevelopment and application of human organs and tissues in vitro\nOver the past few years\, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues\, drug discovery\, predictivity and validation\, and safety and toxicity.\n\nSMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip\, microphysiological systems\, applications of technology and case studies\, imaging\, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field. \nBioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems. \nFor the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma\, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy\, drug screening and extracellular matrix scaffolds. \nEvent Hashtag: #SMi3DCellCulture \nFEATURED SPEAKERS INCLUDE: \n\nLeonard Both\, Senior Quality Assessor\, Biologicals/Biotechnology Unit\, MHRA\nVeronique Barban\, Expert Virology\, Research and Nonclinical Safety Department\, Sanofi Pasteur\nSimone Stahl\, Associate Principal Scientist\, ADME Sciences\, Clinical Pharmacology and Safety Sciences\, AstraZeneca\nWendy Rowan\, Scientific Director\, Novel Human Genetics Research Unit\, GSK\nJason Ekert\, Head of Complex In Vitro Models\, GSK\nSamuel Jackson\, Programme Manager\, Disease Models Efficacy and Safety Pharmacology\, NC3RS\n\nKEY TOPICS FOR 2019 INCLUDE: \n\nLearn from leading pharma companies to benchmark against their applications of 3D technology\nExplore case studies of 3D cell culture\, high throughput screening\, imaging and microphysiological systems in industry\nHear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models\nDiscuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research\nParticipate in a panel discussion on adopting new technologies for 3D models\n\nView the full agenda: http://www.3d-cellculture.com/PJWL \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist \nAcademia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering \nSolution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer \nEARLY BIRD-RATES \n\nREGISTER BY 31ST OCTOBER AND SAVE £400\nREGISTER BY 29TH NOVEMBER AND SAVE £200\nREGISTER BY 13TH DECEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-4th-annual-3d-cell-culture/
LOCATION:Copthorne Tara Hotel\, London\, UK\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR